Cisco’s stock drops 7% on mediocre forecast even as earnings and revenue top estimates
Cisco reported revenue growth in the quarter of close to 10%, topping analysts’ estimates.
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
These funds protect against market drops. Demand is booming
Buffer ETFs could see assets quadruple over a five-year period, according to Cerulli Associates. What to know before investing.
Tariff revenue soars more than 300% as U.S. awaits Supreme Court decision
The U.S. government in January ran up a smaller deficit than a year ago, while tariff collections surged.
Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
Doustdar said Medicare coverage and the launch of Novo’s new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
Oil rises more than 1% on US–Iran tensions, improved demand
U.S. President Donald Trump said on Tuesday he was considering sending a second aircraft carrier to the Middle East.
House votes to override Trump’s Canada tariffs
Republican House leaders tried, and failed, to pass a measure on Tuesday that would have blocked House disapproval votes on Trump tariffs through July.
Heineken to slash up to 6,000 jobs in AI ‘productivity savings’ amid slump in beer sales
Heineken’s CEO told CNBC that AI will play an “important part of ongoing productivity savings” after the brewer said it plans to cut up to 7% of its workforce.
Kraft Heinz pauses work to split the company as new CEO says ‘challenges are fixable’
Kraft Heinz CEO Steve Cahillane said many of the company’s issues are “fixable.”
Tariff bills across U.S. states mount as affordability and Trump head for midterm elections showdown
New data shows that states where key midterm elections races will take place paid over $134 billion in tariffs during 2025 as affordability issues mounted.
